Longeveron Inc.

About Longeveron Inc.

Longeveron is a clinical-stage regenerative medicine biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions. Their mission is to improve healthspan by repairing and regenerating tissue at the site of damage, inflammation, and disease using stem cell therapies.

Products & Services

Laromestrocel (Lomecel-B™):A cellular therapy product being evaluated for treating conditions such as Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease, and Aging Frailty through clinical trials.

CDMO Services:Contract Development and Manufacturing Organization services to support the production of cellular therapies.

Lomecel-B™ (laromestrocel)

Specialties

Stem Cell Therapies Cellular Therapies for Aging-Related Conditions Treatment for Hypoplastic Left Heart Syndrome (HLHS) Treatment for Alzheimer's Disease Treatment for Aging Frailty Healthspan Improvement Regenerative medicine Cellular therapies Hypoplastic Left Heart Syndrome (HLHS) Alzheimer’s disease Aging Frailty

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 30000000 MR: - FA: up to $30 million FAN: 30000000	D: 2026-03-11 FD: 2026-03-11	4 investors
2	RT: Private Placement T: - FT: Private Placement	A: 30000000 MR: - FA: up to $30 million FAN: 30000000	D: 2026-03-10 FD: 2026-03-10	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2025-08-11 FD: 2025-08-11	1 investors
4	RT: Public Offering T: - FT: Public Offering	A: 17500000 MR: - FA: Up to $17.5 Million FAN: 17500000	D: 2025-08-08 FD: 2025-08-08	1 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9000000 MR: - FA: 9.0 million FAN: 9000000	D: 2024-07-19 FD: 2024-07-19	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9000000 MR: - FA: $9.0 million FAN: 9000000	D: 2024-07-18 FD: 2024-07-18	1 investors
7	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4400000 MR: - FA: 4.4 million FAN: 4400000	D: 2024-06-18 FD: 2024-06-18	-
8	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4400000 MR: - FA: 4.4 million FAN: 4400000	D: 2024-06-17 FD: 2024-06-17	1 investors
9	RT: Warrant Exercise and Public Offering T: - FT: Warrant Exercise and Public Offering	A: 11400000 MR: - FA: $11.4 million FAN: 11400000	D: 2024-04-18 FD: 2024-04-18	-
10	RT: Private Placement T: - FT: Private Placement	A: 6200000 MR: - FA: 6.2 million FAN: 6200000	D: 2024-04-17 FD: 2024-04-17	-
11	RT: Public Offering T: - FT: Public Offering	A: 5200000 MR: - FA: $5.2 million FAN: 5200000	D: 2024-04-11 FD: 2024-04-11	2 investors
12	RT: Public Offering T: - FT: Public Offering	A: 5250000 MR: - FA: $5.25 million FAN: 5250000	D: 2024-04-08 FD: 2024-04-08	2 investors
13	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2360000 MR: - FA: 2.36 million FAN: 2360000	D: 2023-12-22 FD: 2023-12-22	-
14	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2360000 MR: - FA: $2.36 million FAN: 2360000	D: 2023-12-21 FD: 2023-12-21	1 investors
15	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: approximately $4 million FAN: 4000000	D: 2023-10-13 FD: 2023-10-13	-
16	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2023-10-12 FD: 2023-10-12	-
17	RT: Rights Offering T: - FT: Rights Offering	A: 3 MR: - FA: $3.00 FAN: 3	D: 2023-08-22 FD: 2023-08-22	-
18	RT: Rights Offering T: - FT: Rights Offering	A: 3 MR: - FA: $3.00 per share FAN: 3	D: 2023-08-16 FD: 2023-08-16	-
19	RT: Rights Offering T: - FT: Rights Offering	A: 3000000 MR: - FA: 3.00 FAN: 3000000	D: 2023-08-14 FD: 2023-08-14	-
20	RT: Rights Offering T: - FT: Rights Offering	A: 30000000 MR: - FA: up to $30,000,000 FAN: 30000000	D: 2023-06-27 FD: 2023-06-27	-

Private Placement Latest

2026-03-11

$30.0M

4 investors (Pro only)

Private Placement 2026-03-10

$30.0M

Public Offering 2025-08-11

$5.0M

View 19 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stephen H. Willard

Chief Executive Officer

J

Joshua M. Hare

Co-Founder, Chief Science Officer and Executive Chairman

L

Lisa Locklear

Chief Financial Officer

N

Nataliya Agafonova

Chief Medical Officer

P

Paul Lehr

General Counsel and Secretary

D

Devin Blass

Chief Technology Officer and Sr. Vice President, CMC

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Longeveron Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised